Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Trial · NCT01275677
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Alive and Free From Invasive Disease (IDFS) | Arm I (Chemotherapy) | 89.2 | percentage of patients | ||
| Percentage of Patients Alive and Free From Invasive Disease (IDFS) | Arm II (Chemotherapy, Trastuzumab) | 89.8 | percentage of patients | ||
| Percentage of Patients Alive and Disease-Free (DFS-DCIS) | Arm I (Chemotherapy) | 89.1 | percentage of patients | ||
| Percentage of Patients Alive and Disease-Free (DFS-DCIS) | Arm II (Chemotherapy, Trastuzumab) | 89.6 | percentage of patients | ||
| Percentage of Patients Alive and Free From Breast Cancer (BCFS) | Arm I (Chemotherapy) | 91.0 | percentage of patients | ||
| Percentage of Patients Alive and Free From Breast Cancer (BCFS) | Arm II (Chemotherapy, Trastuzumab) | 90.7 | percentage of patients | ||
| Percentage of Patients Alive and Recurrence-Free (RFI) | Arm I (Chemotherapy) | 92.3 | percentage of patients | ||
| Percentage of Patients Alive and Recurrence-Free (RFI) | Arm II (Chemotherapy, Trastuzumab) | 92.0 | percentage of patients | ||
| Percentage of Patients Alive and Free From Distant Recurrence (DRFI) | Arm I (Chemotherapy) | 93.6 | percentage of patients | ||
| Percentage of Patients Alive and Free From Distant Recurrence (DRFI) | Arm II (Chemotherapy, Trastuzumab) | 92.7 | percentage of patients | ||
| Percentage of Patients Alive (Overall Survival) | Arm I (Chemotherapy) | 96.3 | percentage of patients alive | ||
| Percentage of Patients Alive (Overall Survival) | Arm II (Chemotherapy, Trastuzumab) | 94.8 | percentage of patients alive | ||
| Toxicity Assessed by Adverse Events | Arm I (Chemotherapy) | 90.9 | percentage of patients | ||
| Toxicity Assessed by Adverse Events | Arm II (Chemotherapy, Trastuzumab) | 94.1 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01275677/results